SEC Form 4 · accession 0001193125-26-294873
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anula Jayasuriya
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.30 | Jul 1, 2026 | A | 125,000 | A | — | Jul 1, 2036 | Common Shares | 125,000 | 125,000 | D |
Explanation of responses
- F1Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.